Patz EF Jr - Search Results

1

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Clarke JM, Simon GR, Mamdani H, Gu L, Herndon JE 2nd, Stinchcombe TE, Ready N, Crawford J, Sonpavde G, Balevic S, Nixon AB, Campa M, Gottlin EB, Li H, Saxena R, He YW, Antonia S, Patz EF Jr. Clarke JM, et al. Among authors: patz ef jr. Nat Commun. 2025 Jan 2;16(1):93. doi: 10.1038/s41467-024-55092-2. Nat Commun. 2025. PMID: 39747856 Free PMC article. Clinical Trial.

2

Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.

Saxena R, Bushey RT, Campa MJ, Gottlin EB, Guo J, Patz EF Jr, He YW. Saxena R, et al. Among authors: patz ef jr. J Immunol. 2024 May 15;212(10):1589-1601. doi: 10.4049/jimmunol.2300728. J Immunol. 2024. PMID: 38558134

3

Complement factor H: a novel innate immune checkpoint in cancer immunotherapy.

Saxena R, Gottlin EB, Campa MJ, Bushey RT, Guo J, Patz EF Jr, He YW. Saxena R, et al. Among authors: patz ef jr. Front Cell Dev Biol. 2024 Feb 8;12:1302490. doi: 10.3389/fcell.2024.1302490. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38389705 Free PMC article. Review.

4

Perspective: rethinking therapeutic strategies in oncology.

Patz EF Jr, Gottlin EB, Simon GR. Patz EF Jr, et al. Front Oncol. 2024 Jan 10;13:1335987. doi: 10.3389/fonc.2023.1335987. eCollection 2023. Front Oncol. 2024. PMID: 38269024 Free PMC article.

5

Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.

Kocher Wulfeck M, Plesner S, Herndon JE 2nd, Christensen JD, Patz EF Jr. Kocher Wulfeck M, et al. Among authors: patz ef jr. Lung Cancer. 2023 Dec;186:107420. doi: 10.1016/j.lungcan.2023.107420. Epub 2023 Nov 10. Lung Cancer. 2023. PMID: 37956610

6

Response to Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions.

Han DH, Duan F, Patz EF Jr. Han DH, et al. Among authors: patz ef jr. J Thorac Oncol. 2023 Apr;18(4):e41-e42. doi: 10.1016/j.jtho.2023.01.003. J Thorac Oncol. 2023. PMID: 36990579 Free article. No abstract available.

7

Upregulation of complement proteins in lung cancer cells mediates tumor progression.

Kleczko EK, Poczobutt JM, Navarro AC, Laskowski J, Johnson AM, Korpela SP, Gurule NJ, Heasley LE, Hopp K, Weiser-Evans MCM, Gottlin EB, Bushey RT, Campa MJ, Patz EF Jr, Thurman JM, Nemenoff RA. Kleczko EK, et al. Among authors: patz ef jr. Front Oncol. 2023 Jan 5;12:1045690. doi: 10.3389/fonc.2022.1045690. eCollection 2022. Front Oncol. 2023. PMID: 36686777 Free PMC article.

8

Single nucleotide polymorphisms in FOXP1 and RORA of the lymphocyte activation-related pathway affect survival of lung cancer patients.

Du H, Mu R, Liu L, Liu H, Luo S, Patz EF Jr, Glass C, Su L, Du M, Christiani DC, Li H, Wei Q. Du H, et al. Among authors: patz ef jr. Transl Lung Cancer Res. 2022 May;11(5):890-901. doi: 10.21037/tlcr-22-104. Transl Lung Cancer Res. 2022. PMID: 35693292 Free PMC article.

9

Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival.

Chen AS, Liu H, Wu Y, Luo S, Patz EF Jr, Glass C, Su L, Du M, Christiani DC, Wei Q. Chen AS, et al. Among authors: patz ef jr. Mol Carcinog. 2022 Jul;61(7):619-628. doi: 10.1002/mc.23400. Epub 2022 May 3. Mol Carcinog. 2022. PMID: 35502931

10

Prognostic significance of a complement factor H autoantibody in early stage NSCLC.

Gottlin EB, Campa MJ, Gandhi R, Bushey RT, Herndon Nd JE, Patz EF Jr. Gottlin EB, et al. Among authors: patz ef jr. Cancer Biomark. 2022;34(3):385-392. doi: 10.3233/CBM-210355. Cancer Biomark. 2022. PMID: 35068447

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

164 results

Search Page

Filters